| scholarly article | Q13442814 |
| P50 | author | Li Che | Q61160006 |
| Xin Chen | Q88073652 | ||
| Antonio Cigliano | Q43122575 | ||
| P2093 | author name string | Xi Chen | |
| Shu Zhang | |||
| Meng Xu | |||
| Diego F Calvisi | |||
| Pin Liu | |||
| Frank Dombrowski | |||
| Matthias Evert | |||
| Yu Qiao | |||
| Zhong Xu | |||
| Katja Evert | |||
| Silvia Ribback | |||
| Runze Shang | |||
| Rosa M Pascale | |||
| P2860 | cites work | Glucose Catabolism in Liver Tumors Induced by c-MYC Can Be Sustained by Various PKM1/PKM2 Ratios and Pyruvate Kinase Activities | Q46763707 |
| Targets for immunotherapy of liver cancer. | Q47965755 | ||
| mTOR Signaling in Growth, Metabolism, and Disease. | Q54144950 | ||
| Hepatocellular carcinoma | Q57756376 | ||
| mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy | Q64274877 | ||
| A Polymorphic Locus Near the Human Insulin Gene Is Associated with Insulin-dependent Diabetes Melliitus | Q70314155 | ||
| Everolimus | Q87733396 | ||
| Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? | Q27025083 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| MYC on the path to cancer | Q29619979 | ||
| Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E | Q33980041 | ||
| Oncogene-specific formation of chemoresistant murine hepatic cancer stem cells | Q34233172 | ||
| MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer | Q34357796 | ||
| Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial | Q34663499 | ||
| MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase | Q34687185 | ||
| AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer | Q34990362 | ||
| Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression | Q36248716 | ||
| Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells | Q36899877 | ||
| Spontaneous Hepatocellular Carcinoma after the Combined Deletion of Akt Isoforms. | Q37038522 | ||
| Targeted disruption of the protein kinase SGK3/CISK impairs postnatal hair follicle development | Q37497352 | ||
| Akt-mediated foxo1 inhibition is required for liver regeneration. | Q37525730 | ||
| Hydrodynamic transfection for generation of novel mouse models for liver cancer research | Q38183539 | ||
| Current treatment strategies for inhibiting mTOR in cancer | Q38286529 | ||
| Akt2 is required for hepatic lipid accumulation in models of insulin resistance. | Q38349186 | ||
| Signaling crosstalk between the mTOR complexes | Q38700659 | ||
| Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma | Q38722204 | ||
| TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication | Q38726203 | ||
| TORC2 Structure and Function | Q38830534 | ||
| mTORC1 signaling and the metabolic control of cell growth | Q39243905 | ||
| Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo | Q39491650 | ||
| Expansion of hepatic tumor progenitor cells in Pten-null mice requires liver injury and is reversed by loss of AKT2. | Q39656536 | ||
| Loss of Akt1 in mice increases energy expenditure and protects against diet-induced obesity | Q40313842 | ||
| Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade | Q42468960 | ||
| Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1 | Q42592859 | ||
| Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice. | Q45870005 | ||
| A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis. | Q46519493 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 1600-1613 | |
| P577 | publication date | 2019-06-21 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | The mTORC2-Akt1 Cascade Is Crucial for c-Myc to Promote Hepatocarcinogenesis in Mice and Humans | |
| P478 | volume | 70 |
| Q90383817 | Experimental Models to Define the Genetic Predisposition to Liver Cancer |
| Q94566583 | Role of the mTOR pathway in liver cancer: from molecular genetics to targeted therapies |
| Q89537463 | Up-Regulated CCDC34 Contributes to the Proliferation and Metastasis of Hepatocellular Carcinoma |
Search more.